Leading BioSciences, Inc.

Leading BioSciences, Inc. (LBS) is a biopharmaceutical company that has developed a revolutionary medical platform based on the science of autodigestion. The company’s lead candidate (LB1148) is a therapeutic for severe sepsis, septic shock, and multi-organ failure. In addition, the company is developing a breath and blood diagnostic for early detection of acute shock and multi-organ failure. This therapy is part of an overall product design that includes the pharmaceutical formulation (LB1148) and the delivery device. To date, this new medical platform has produced 14 different products, therapies, and medical devices each with their own distinct patents and exclusive licenses.